Singh S, Patel N, Soundararajan A, Pattabiraman P
Res Sq. 2025; .
PMID: 39764143
PMC: 11703349.
DOI: 10.21203/rs.3.rs-5690041/v1.
Cohen-Davidi E, Feinstein V, Knyazer B, Beit-Yannai E, Veksler-Lublinsky I
Invest Ophthalmol Vis Sci. 2024; 65(14):38.
PMID: 39728693
PMC: 11684117.
DOI: 10.1167/iovs.65.14.38.
Yang Y, Zhou H, Hong Z
Front Nutr. 2024; 11:1461748.
PMID: 39512517
PMC: 11541052.
DOI: 10.3389/fnut.2024.1461748.
Ren J, Xiao Y, Wang D, Cui H, Zhao R, Guo Z
Dose Response. 2024; 22(4):15593258241298062.
PMID: 39484664
PMC: 11526272.
DOI: 10.1177/15593258241298062.
Kim E, Walker B, Hopkins N, Fowler S, Jerkins B, Kanner E
J Clin Med. 2024; 13(19).
PMID: 39407813
PMC: 11476880.
DOI: 10.3390/jcm13195753.
Profiling the cell diversity and tissue structure of aqueous humor circulatory system in human eyes using spatial single-cell RNA sequencing.
Yuan H, Song Z, Sun X, Song C, Guo L, Zhang Q
Genes Dis. 2024; 12(1):101304.
PMID: 39403690
PMC: 11472072.
DOI: 10.1016/j.gendis.2024.101304.
Novel therapeutic targets for primary open-angle glaucoma identified through multicenter proteome-wide mendelian randomization.
Yuan W, Li J, Gao S, Sun W, Zhao F
Front Pharmacol. 2024; 15:1428472.
PMID: 39221148
PMC: 11362091.
DOI: 10.3389/fphar.2024.1428472.
Deepening insights into cholinergic agents for intraocular pressure reduction: systems genetics, molecular modeling, and perspectives.
Kim M, Ibrahim M, Jablonski M
Front Mol Biosci. 2024; 11:1423351.
PMID: 39130374
PMC: 11310038.
DOI: 10.3389/fmolb.2024.1423351.
Role of integrins in the development of fibrosis in the trabecular meshwork.
Faralli J, Filla M, Peters D
Front Ophthalmol (Lausanne). 2024; 3:1274797.
PMID: 38983065
PMC: 11182094.
DOI: 10.3389/fopht.2023.1274797.
Differential protein expression and metabolite profiling in glaucoma: Insights from a multi-omics analysis.
Mok J, Park D, Han J
Biofactors. 2024; 50(6):1220-1235.
PMID: 38818964
PMC: 11627470.
DOI: 10.1002/biof.2079.
Steroid-Induced Ocular Hypertension in Mice Is Differentially Reduced by Selective EP2, EP3, EP4, and IP Prostanoid Receptor Agonists.
Sharif N, Millar J, Zode G, Ota T
Int J Mol Sci. 2024; 25(6).
PMID: 38542305
PMC: 10970031.
DOI: 10.3390/ijms25063328.
Digital spatial profiling of segmental outflow regions in trabecular meshwork reveals a role for ADAM15.
Faralli J, Filla M, Yang Y, Sun Y, Johns K, Keller K
PLoS One. 2024; 19(2):e0298802.
PMID: 38394161
PMC: 10889904.
DOI: 10.1371/journal.pone.0298802.
Influence of Growth Differentiation Factor 15 on Intraocular Pressure in Mice.
Maddala R, Eldawy C, Ho L, Challa P, Rao P
Lab Invest. 2024; 104(4):102025.
PMID: 38290601
PMC: 11031300.
DOI: 10.1016/j.labinv.2024.102025.
scAAV2-Mediated Expression of Thioredoxin 2 and C3 Transferase Prevents Retinal Ganglion Cell Death and Lowers Intraocular Pressure in a Mouse Model of Glaucoma.
Kim H, Cha S, Choi J, Lee J, Kim K, Kim J
Int J Mol Sci. 2023; 24(22).
PMID: 38003443
PMC: 10671512.
DOI: 10.3390/ijms242216253.
Role of Glucocorticoids and Glucocorticoid Receptors in Glaucoma Pathogenesis.
Patel P, Kodati B, Clark A
Cells. 2023; 12(20).
PMID: 37887296
PMC: 10605158.
DOI: 10.3390/cells12202452.
Exosome-based crosstalk in glaucoma pathogenesis: a focus on oxidative stress and neuroinflammation.
Wang L, Wei X
Front Immunol. 2023; 14:1202704.
PMID: 37529047
PMC: 10388248.
DOI: 10.3389/fimmu.2023.1202704.
Sigma-1 Receptor Activation Is Protective against TGFβ2-Induced Extracellular Matrix Changes in Human Trabecular Meshwork Cells.
Tran M, Medveczki T, Besztercei B, Torok G, Szabo A, Gasull X
Life (Basel). 2023; 13(7).
PMID: 37511956
PMC: 10381521.
DOI: 10.3390/life13071581.
New Biomarker Combination Related to Oxidative Stress and Inflammation in Primary Open-Angle Glaucoma.
Dammak A, Sanchez Naves J, Huete-Toral F, Carracedo G
Life (Basel). 2023; 13(7).
PMID: 37511830
PMC: 10381240.
DOI: 10.3390/life13071455.
Glaucomatous aqueous humor vesicles are smaller and differ in composition compared to controls.
Mueller A, Anter A, Edwards G, Junk A, Liu Y, Ziebarth N
Exp Eye Res. 2023; 234:109562.
PMID: 37385533
PMC: 10528935.
DOI: 10.1016/j.exer.2023.109562.
Recently Approved Drugs for Lowering and Controlling Intraocular Pressure to Reduce Vision Loss in Ocular Hypertensive and Glaucoma Patients.
Sharif N
Pharmaceuticals (Basel). 2023; 16(6).
PMID: 37375739
PMC: 10304251.
DOI: 10.3390/ph16060791.